Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Sangamo Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Patrick Trucchio maintains $Sangamo Therapeutics(SGMO.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate
Earnings Update: Here's Why Analysts Just Lifted Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target To US$3.80
Q2 2024 Sangamo Therapeutics Inc Earnings Call